RESEARCH · BPC-157 + TB-500 · EYE MODELS
BPC-157 and TB-500 in Eye Research: Corneal Wounds, Pupil Control, a Rat Glaucoma Model and Retinal Ischaemia
PurixLab’s BPC-157 + TB-500 10mg vial combines two research peptides: BPC-157, the 15-amino-acid sequence GEPPPGKPADDAGLV, and TB-500, a synthetic peptide built around the acetylated LKKTETQ region of thymosin beta-4 (Tβ4). Our earlier articles cover the molecular mechanisms, nervous system models and the human data gap. This article turns to the eye: corneal wounds, corneal sensation, pupil control, an experimental glaucoma model and retinal ischaemia, plus a short note on where Tβ4 eye research stands. These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Why the eye is a useful test bed
The eye lets researchers watch healing directly. Corneal defects can be stained with fluorescein and photographed, new vessels growing in from the limbus are visible under a microscope, intraocular pressure can be measured with a tonometer, and the retina and optic disc can be examined by fundoscopy and later by histology. The cornea is also normally avascular, so any effect on vessel growth is easy to see. Every BPC-157 eye study we found on PubMed comes from the same Zagreb research group, with P. Sikirić as an author on each paper, so the evidence below has not yet been reproduced elsewhere.
Corneal wounds
Epithelial defects. The first eye study removed the whole corneal epithelium from one eye in 48 rats, split into 4 groups of 12. BPC-157 eye drops at three concentrations, or distilled water, were applied immediately and then every 8 hours up to 40 hours. Healing was markedly faster with the two higher concentrations: lesions had disappeared by 40 h or 48 h, while control lesions were still present at 48 h. The effect was concentration-dependent [1].
Perforating injury. A later study made a penetrating 2-mm incision near the limbus of the rat cornea. With the two effective BPC-157 eye-drop concentrations, fluorescein and Seidel leak tests became negative, epithelial defects closed completely at 72 h or 96 h, and inflammatory cells in the anterior chamber disappeared by 96 h or 120 h. Controls healed poorly and grew new vessels from the limbus toward the wound, whereas treated eyes generally did not, and transparency returned quickly [2].
Corneal anaesthesia. Topical anaesthetics such as tetracaine and oxybuprocaine can damage the corneal surface. In rats given 0.5% tetracaine or 0.4% oxybuprocaine drops, BPC-157 drops fully counteracted the loss of corneal sensation, the surface lesions and the fall in tear volume. The study also used the nitric oxide synthase blocker L-NAME and the substrate L-arginine: L-NAME prolonged insensitivity and worsened lesions, and BPC-157 still restored recovery when given with either agent [3]. The authors go as far as proposing BPC-157 as an antidote to topical anaesthetics; that is their interpretation of a single rat model.
The pupil and nitric oxide
In rats and guinea pigs, BPC-157 given locally or systemically did not change normal pupil size. It did counteract atropine-induced dilation, and it shortened the miosis produced by L-NAME while prolonging that produced by L-arginine. The authors interpret this as BPC-157 taking part in ocular control through nitric oxide-mediated and cholinergic mechanisms [4]. The study shows interactions with these drugs, not a defined receptor or pathway.
An experimental glaucoma model
Cauterising three of the four episcleral veins in rats causes venous congestion, raised intraocular pressure and glaucoma-like damage. In a six-week study, BPC-157 was given as eye drops, intraperitoneally or in drinking water, either just before the surgery or starting 24 h after it. The authors report that all regimens immediately normalised intraocular pressure, and that treated rats had normal pupil diameter, well-preserved retinal ganglion cells and optic nerves, and normal retinal and choroidal vessels, whereas controls showed ganglion cell degeneration, optic nerve head excavation and disc atrophy [5]. Their explanation is that the remaining episcleral vein was rapidly upgraded as a collateral pathway, a mechanism the group has proposed for vessel occlusion models in other organs.
Retinal ischaemia
A single retrobulbar application of L-NAME produced vessel calibre irregularity, optic disc atrophy and faint choroidal vessels in rats, progressing to a severe stage while intraocular pressure stayed normal. BPC-157 given by the same route, either 20 min or 48 h after L-NAME, was followed by only mild changes and then a normal fundus over the 4-week study. Histology at 1, 2 and 4 weeks showed preserved inner retinal layers and normal retinal thickness [6].
Reviews from the same group
Two reviews pull these studies together. A 2023 review proposes BPC-157 as a possible glaucoma therapy and also lists counteracted dry eye after lacrimal gland removal [7]; we did not find a separate PubMed abstract for that dry-eye experiment, so we do not describe it. A 2025 review introduces a “triad” linking corneal ulcer healing, corneal neovascularisation and intraocular pressure, and compares BPC-157 with standard agents in each area [8]. Both are written by the authors of the primary studies.
Thymosin beta-4 and the eye, briefly
Unlike BPC-157, Tβ4 has reached small human eye trials as a 0.1% eye drop (RGN-259) [9], covered in more detail in our cornea and ocular surface article. A 2010 case report described its use for chronic nonhealing neurotrophic corneal defects [10]. In a nine-patient phase 2 trial in severe dry eye, the treated group had 35.1% less ocular discomfort and 59.1% less corneal staining than vehicle at day 56 [9]. A larger phase II study in 72 subjects did not meet either primary endpoint, although some secondary measures improved [11]. In mice with bacterial keratitis, Tβ4 added to ciprofloxacin improved corneal nerve regeneration and visual function more than either agent alone [12]. These studies used full-length Tβ4, not the short TB-500 fragment.
What remains open
- One laboratory. All BPC-157 eye data come from a single group, with no independent replication [1,2,5,6].
- No human eye data for BPC-157. We found no clinical eye study of BPC-157 on PubMed; the human ocular evidence that exists concerns full-length Tβ4 [9,11].
- Mechanism. Nitric oxide and collateral-vessel explanations are inferred from drug-interaction experiments rather than shown with molecular tools [4,5].
- The blend. No eye study has tested BPC-157 and TB-500 together.
BPC-157 + TB-500 10mg at PurixLab
BPC-157 + TB-500 10mg: a labelled lyophilized research vial with BPC-157 5mg + TB-500 5mg per vial (10mg total), C$89 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/bpc-157-tb-500-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Lazić R, Gabrić N, Dekaris I, et al. Gastric pentadecapeptide BPC 157 promotes corneal epithelial defects healing in rats. Coll Antropol. 2005;29(1):321-5. PubMed 16117343
- Masnec S, Kokot A, Zlatar M, et al. Perforating corneal injury in rat and pentadecapeptide BPC 157. Exp Eye Res. 2015;136:9-15. PubMed 25912999 · doi:10.1016/j.exer.2015.04.016
- Mirković I, Kralj T, Lozić M, et al. Pentadecapeptide BPC 157 shortens duration of tetracaine- and oxybuprocaine-induced corneal anesthesia in rats. Acta Clin Croat. 2020;59(3):394-406. PubMed 34177048 · PMC8212645 · doi:10.20471/acc.2020.59.03.02
- Kokot A, Zlatar M, Stupnisek M, et al. NO system dependence of atropine-induced mydriasis and L-NAME- and L-arginine-induced miosis: Reversal by the pentadecapeptide BPC 157 in rats and guinea pigs. Eur J Pharmacol. 2016;771:211-9. PubMed 26698393 · doi:10.1016/j.ejphar.2015.12.016
- Kralj T, Kokot A, Zlatar M, et al. Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma. Biomedicines. 2021;10(1):89. PubMed 35052769 · PMC8773185 · doi:10.3390/biomedicines10010089
- Zlatar M, Kokot A, Vuletic LB, et al. BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats. Front Pharmacol. 2021;12:632295. PubMed 34177567 · PMC8222724 · doi:10.3389/fphar.2021.632295
- Sikiric P, Kokot A, Kralj T, et al. Stable Gastric Pentadecapeptide BPC 157-Possible Novel Therapy of Glaucoma and Other Ocular Conditions. Pharmaceuticals (Basel). 2023;16(7):1052. PubMed 37513963 · PMC10385428 · doi:10.3390/ph16071052
- Masnec S, Kokot A, Kralj T, et al. Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy. Pharmaceuticals (Basel). 2025;18(12):1822. PubMed 41471311 · PMC12735534 · doi:10.3390/ph18121822
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-6. PubMed 25826322 · doi:10.1097/ICO.0000000000000379
- Dunn SP, Heidemann DG, Chow CY, et al. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4. Arch Ophthalmol. 2010;128(5):636-8. PubMed 20457990 · doi:10.1001/archophthalmol.2010.53
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84. PubMed 26056426 · PMC4445951 · doi:10.2147/OPTH.S80954
- Ebrahim AS, Liu L, Carion TW, et al. Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function. Invest Ophthalmol Vis Sci. 2026;67(6):22. PubMed 42283548 · PMC13274770 · doi:10.1167/iovs.67.6.22